Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results, Misses Expectations By $0.08 EPS

Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings data on Tuesday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.08), FiscalAI reports. The company had revenue of $13.82 million during the quarter, compared to analyst estimates of $11.42 million.

Aquestive Therapeutics Price Performance

NASDAQ:AQST traded up $0.12 during trading hours on Tuesday, hitting $4.41. The stock had a trading volume of 6,411,656 shares, compared to its average volume of 3,020,570. Aquestive Therapeutics has a one year low of $2.93 and a one year high of $7.55. The firm has a market capitalization of $553.32 million, a price-to-earnings ratio of -7.23 and a beta of 1.49. The company has a 50 day simple moving average of $4.12 and a two-hundred day simple moving average of $4.06.

Analysts Set New Price Targets

Several research firms have recently weighed in on AQST. Oppenheimer began coverage on Aquestive Therapeutics in a research note on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen upgraded shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Aquestive Therapeutics has an average rating of “Buy” and an average target price of $8.50.

Insider Transactions at Aquestive Therapeutics

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the completion of the transaction, the director owned 25,000 shares of the company’s stock, valued at $125,500. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the transaction, the chief executive officer directly owned 660,574 shares in the company, valued at approximately $2,833,862.46. This represents a 1.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by corporate insiders.

Institutional Trading of Aquestive Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in shares of Aquestive Therapeutics by 17.0% during the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock worth $72,000 after acquiring an additional 1,862 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Aquestive Therapeutics by 6.0% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock valued at $156,000 after buying an additional 2,649 shares during the period. Informed Momentum Co LLC lifted its stake in shares of Aquestive Therapeutics by 1.8% in the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock valued at $1,002,000 after acquiring an additional 2,721 shares during the last quarter. Stifel Financial Corp grew its position in Aquestive Therapeutics by 0.9% during the 4th quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after acquiring an additional 3,300 shares during the last quarter. Finally, AQR Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 6.8% during the fourth quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after purchasing an additional 3,934 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.

Key Headlines Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: Aquestive reported positive topline human-factors and pharmacokinetic study results for Anaphylm™ (dibutepinephrine) sublingual film. The findings indicated improvements in how users handled and administered the potential anaphylaxis treatment, supporting the product’s usability and regulatory prospects. Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm
• Positive Sentiment: The encouraging Anaphylm study news prompted a sharp move in the stock in the prior session, highlighting the candidate’s importance to Aquestive’s valuation. If development and regulatory milestones remain positive, Anaphylm could provide a significant future commercial opportunity. Aquestive Therapeutics shares jump after encouraging Anaphylm study results
• Neutral Sentiment: Aquestive released second-quarter 2026 financial results and a strategic business update. The announcement gives investors additional information on operating performance and Anaphylm development, but the supplied report does not include enough detail to assess the quarter’s results independently. Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Aquestive’s updated fiscal 2026 revenue guidance of $46.0 million to $50.0 million is below the $50.8 million analyst consensus at the midpoint. The reduced outlook may weigh on sentiment by signaling slower-than-expected near-term revenue growth, although the positive Anaphylm data partially offsets the concern.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.